Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25676070 | 1.00 | GPR84 (0.50) | GPR84FFAR1CA2CA1MAPK1 | |
| SCHEMBL25676077 | 1.00 | GPR84 (0.50) | GPR84FFAR1CA2CA1MAPK1 | |
| SCHEMBL27050890 | 0.91 | GPR84 (0.63) | GPR84FFAR1CA1 | |
| SCHEMBL25834791 | 0.91 | GPR84 (0.63) | GPR84FFAR1CA1 | |
| SCHEMBL533291 | 0.87 | GPR84 (0.56) | GPR84FFAR1CA2CA1MAPK1 | |
| SCHEMBL637778 | 0.85 | CHRM1 (0.40) | GPR84FFAR1CA2CA1 | |
| SCHEMBL25676073 | 0.85 | CHRM1 (0.40) | GPR84FFAR1CA2CA1 | |
| SCHEMBL26811 | 0.85 | CHRM1 (0.40) | GPR84FFAR1CA2CA1 | |
| SCHEMBL7045666 | 0.80 | GPR84 (0.67) | GPR84FFAR1CA1 | |
| SCHEMBL24804495 | 0.79 | GABRR1 (0.38) | GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673907-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673907-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | REVAGENIX, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-8658606-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8653041-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653042-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130178438-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8318685-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120122809-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673907-B2 | Modular synthesis of aminoglycosides | MRPL21, COASY, AARS1 | GPR84 4815/4885FFAR1 4816/4885CA2 4693/4885 |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | GPR84 4634/4885FFAR1 4506/4885CA2 4657/4885 |
| US-20130178438-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | NQO2, NQO1, MRPL21 | GPR84 4632/4885FFAR1 4598/4885CA2 4577/4885 |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | GPR84 4577/4885FFAR1 4383/4885CA2 4675/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | GPR84 1419/4885FFAR1 1171/4885CA2 4194/4885 |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | GPR84 4502/4885FFAR1 4267/4885CA2 4665/4885 |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | GPR84 4548/4885FFAR1 4398/4885CA2 4664/4885 |
| US-20120122809-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | NQO2, NQO1, MRPL21 | GPR84 4632/4885FFAR1 4598/4885CA2 4577/4885 |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QTRT1 | GPR84 4643/4885FFAR1 4229/4885CA2 4519/4885 |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | MRPL21, COASY, AARS1 | GPR84 4815/4885FFAR1 4816/4885CA2 4693/4885 |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | GPR84 4502/4885FFAR1 4267/4885CA2 4665/4885 |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, QARS1, NQO2 | GPR84 4565/4885FFAR1 4271/4885CA2 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.